Build Your Comparison

Side-by-side financial analysis
BLLN logo
BLLN
NTRA logo
NTRA
Try popular comparisons:

Stock Comparison

BLLN vs NTRA

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
BLLN
BillionToOne, Inc.

Medical - Diagnostics & Research

HealthcareNASDAQ • US
Market Cap$4.65B
5Y Perf.-1.5%
NTRA
Natera, Inc.

Medical - Diagnostics & Research

HealthcareNASDAQ • US
Market Cap$30.37B
5Y Perf.+15.4%

BLLN vs NTRA — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
BLLN logoBLLN
NTRA logoNTRA
IndustryMedical - Diagnostics & ResearchMedical - Diagnostics & Research
Market Cap$4.65B$30.37B
Revenue (TTM)$355M$2.50B
Net Income (TTM)$25M$-226M
Gross Margin70.4%65.2%
Operating Margin10.2%-13.0%
Forward P/E102.7x
Total Debt$109M$214M
Cash & Equiv.$496M$1.08B

Quick Verdict: BLLN vs NTRA

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: BLLN and NTRA are tied at the top with 3 categories each — the right choice depends on your priorities. Natera, Inc. is the stronger pick specifically for valuation and capital efficiency and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
BLLN
BillionToOne, Inc.
The Growth Play

BLLN has the current edge in this matchup, primarily because of its strength in growth exposure.

  • Rev growth 100.0%, EPS growth 106.8%
  • 100.0% revenue growth vs NTRA's 35.9%
  • 7.1% margin vs NTRA's -9.0%
Best for: growth exposure
NTRA
Natera, Inc.
The Income Pick

NTRA is the clearest fit if your priority is income & stability and long-term compounding.

  • beta 1.24
  • 17.3% 10Y total return vs BLLN's -7.2%
  • Lower volatility, beta 1.24, Low D/E 12.5%, current ratio 3.39x
Best for: income & stability and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthBLLN logoBLLN100.0% revenue growth vs NTRA's 35.9%
ValueNTRA logoNTRABetter valuation composite
Quality / MarginsBLLN logoBLLN7.1% margin vs NTRA's -9.0%
Stability / SafetyNTRA logoNTRABeta 1.24 vs BLLN's 1.91, lower leverage
DividendsTieNeither stock pays a meaningful dividend
Momentum (1Y)NTRA logoNTRA+29.0% vs BLLN's -7.2%
Efficiency (ROA)BLLN logoBLLN5.1% ROA vs NTRA's -10.4%, ROIC 13.5% vs -36.1%

BLLN vs NTRA — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

Discover the Biotech & Healthcare Stocks Theme

These companies are key players in the Biotech & Healthcare Stocks ecosystem. See how they stack up against the rest of the sector.

Explore Theme
BLLNBillionToOne, Inc.

Segment breakdown not available.

NTRANatera, Inc.
FY 2025
Product
99.6%$2.3B
Licensing and other
0.4%$10M

BLLN vs NTRA — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLNTRALAGGINGBLLN

Income & Cash Flow (Last 12 Months)

BLLN leads this category, winning 6 of 6 comparable metrics.

NTRA is the larger business by revenue, generating $2.5B annually — 7.1x BLLN's $355M. BLLN is the more profitable business, keeping 7.1% of every revenue dollar as net income compared to NTRA's -9.0%. On growth, BLLN holds the edge at +83.8% YoY revenue growth, suggesting stronger near-term business momentum.

MetricBLLN logoBLLNBillionToOne, Inc.NTRA logoNTRANatera, Inc.
RevenueTrailing 12 months$355M$2.5B
EBITDAEarnings before interest/tax$44M-$313M
Net IncomeAfter-tax profit$25M-$226M
Free Cash FlowCash after capex$28M$92M
Gross MarginGross profit ÷ Revenue+70.4%+65.2%
Operating MarginEBIT ÷ Revenue+10.2%-13.0%
Net MarginNet income ÷ Revenue+7.1%-9.0%
FCF MarginFCF ÷ Revenue+7.9%+3.7%
Rev. Growth (YoY)Latest quarter vs prior year+83.8%+38.8%
EPS Growth (YoY)Latest quarter vs prior year+4.8%-20.0%
BLLN leads this category, winning 6 of 6 comparable metrics.

Valuation Metrics

NTRA leads this category, winning 3 of 4 comparable metrics.
MetricBLLN logoBLLNBillionToOne, Inc.NTRA logoNTRANatera, Inc.
Market CapShares × price$4.7B$30.4B
Enterprise ValueMkt cap + debt − cash$4.3B$29.5B
Trailing P/EPrice ÷ TTM EPS1587.44x-139.52x
Forward P/EPrice ÷ next-FY EPS est.102.72x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple266.12x
Price / SalesMarket cap ÷ Revenue15.24x13.17x
Price / BookPrice ÷ Book value/share9.65x16.93x
Price / FCFMarket cap ÷ FCF295.98x278.35x
NTRA leads this category, winning 3 of 4 comparable metrics.

Profitability & Efficiency

BLLN leads this category, winning 7 of 9 comparable metrics.

BLLN delivers a 7.6% return on equity — every $100 of shareholder capital generates $8 in annual profit, vs $-15 for NTRA. NTRA carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to BLLN's 0.23x. On the Piotroski fundamental quality scale (0–9), BLLN scores 7/9 vs NTRA's 5/9, reflecting strong financial health.

MetricBLLN logoBLLNBillionToOne, Inc.NTRA logoNTRANatera, Inc.
ROE (TTM)Return on equity+7.6%-15.1%
ROA (TTM)Return on assets+5.1%-10.4%
ROICReturn on invested capital+13.5%-36.1%
ROCEReturn on capital employed+3.7%-18.3%
Piotroski ScoreFundamental quality 0–975
Debt / EquityFinancial leverage0.23x0.13x
Net DebtTotal debt minus cash-$387M-$862M
Cash & Equiv.Liquid assets$496M$1.1B
Total DebtShort + long-term debt$109M$214M
Interest CoverageEBIT ÷ Interest expense516.43x-34.29x
BLLN leads this category, winning 7 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

NTRA leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in NTRA five years ago would be worth $20,440 today (with dividends reinvested), compared to $9,282 for BLLN. Over the past 12 months, NTRA leads with a +29.0% total return vs BLLN's -7.2%. The 3-year compound annual growth rate (CAGR) favors NTRA at 62.4% vs BLLN's -2.5% — a key indicator of consistent wealth creation.

MetricBLLN logoBLLNBillionToOne, Inc.NTRA logoNTRANatera, Inc.
YTD ReturnYear-to-date+13.2%-7.3%
1-Year ReturnPast 12 months-7.2%+29.0%
3-Year ReturnCumulative with dividends-7.2%+328.7%
5-Year ReturnCumulative with dividends-7.2%+104.4%
10-Year ReturnCumulative with dividends-7.2%+1731.3%
CAGR (3Y)Annualised 3-year return-2.5%+62.4%
NTRA leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

NTRA leads this category, winning 2 of 2 comparable metrics.

NTRA is the less volatile stock with a 1.24 beta — it tends to amplify market swings less than BLLN's 1.91 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NTRA currently trades 82.7% from its 52-week high vs BLLN's 72.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricBLLN logoBLLNBillionToOne, Inc.NTRA logoNTRANatera, Inc.
Beta (5Y)Sensitivity to S&P 5001.91x1.24x
52-Week HighHighest price in past year$138.70$256.36
52-Week LowLowest price in past year$61.96$131.81
% of 52W HighCurrent price vs 52-week peak+72.9%+82.7%
RSI (14)Momentum oscillator 0–10056.555.9
Avg Volume (50D)Average daily shares traded642K1.4M
NTRA leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Wall Street rates BLLN as "Buy" and NTRA as "Buy". Consensus price targets imply 23.6% upside for BLLN (target: $125) vs 23.1% for NTRA (target: $261).

MetricBLLN logoBLLNBillionToOne, Inc.NTRA logoNTRANatera, Inc.
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$125.00$261.00
# AnalystsCovering analysts427
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

NTRA leads in 3 of 6 categories (Valuation Metrics, Total Returns). BLLN leads in 2 (Income & Cash Flow, Profitability & Efficiency).

Best OverallNatera, Inc. (NTRA)Leads 3 of 6 categories
Loading custom metrics...

BLLN vs NTRA: Frequently Asked Questions

9 questions · data-driven answers · updated daily

01

Is BLLN or NTRA a better buy right now?

For growth investors, BillionToOne, Inc.

(BLLN) is the stronger pick with 100. 0% revenue growth year-over-year, versus 35. 9% for Natera, Inc. (NTRA). BillionToOne, Inc. (BLLN) offers the better valuation at 1587. 4x trailing P/E (102. 7x forward), making it the more compelling value choice. Analysts rate BillionToOne, Inc. (BLLN) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — BLLN or NTRA?

Over the past 5 years, Natera, Inc.

(NTRA) delivered a total return of +104. 4%, compared to -7. 2% for BillionToOne, Inc. (BLLN). Over 10 years, the gap is even starker: NTRA returned +1731% versus BLLN's -7. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — BLLN or NTRA?

By beta (market sensitivity over 5 years), Natera, Inc.

(NTRA) is the lower-risk stock at 1. 24β versus BillionToOne, Inc. 's 1. 91β — meaning BLLN is approximately 54% more volatile than NTRA relative to the S&P 500. On balance sheet safety, Natera, Inc. (NTRA) carries a lower debt/equity ratio of 13% versus 23% for BillionToOne, Inc. — giving it more financial flexibility in a downturn.

04

Which is growing faster — BLLN or NTRA?

By revenue growth (latest reported year), BillionToOne, Inc.

(BLLN) is pulling ahead at 100. 0% versus 35. 9% for Natera, Inc. (NTRA). On earnings-per-share growth, the picture is similar: BillionToOne, Inc. grew EPS 106. 8% year-over-year, compared to 0. 7% for Natera, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — BLLN or NTRA?

BillionToOne, Inc.

(BLLN) is the more profitable company, earning 2. 4% net margin versus -9. 0% for Natera, Inc. — meaning it keeps 2. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BLLN leads at 5. 3% versus -13. 4% for NTRA. At the gross margin level — before operating expenses — BLLN leads at 68. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Is BLLN or NTRA more undervalued right now?

Analyst consensus price targets imply the most upside for BLLN: 23.

6% to $125. 00.

07

Which pays a better dividend — BLLN or NTRA?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

08

Is BLLN or NTRA better for a retirement portfolio?

For long-horizon retirement investors, Natera, Inc.

(NTRA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 24), +1731% 10Y return). BillionToOne, Inc. (BLLN) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NTRA: +1731%, BLLN: -7. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

09

What are the main differences between BLLN and NTRA?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.